Skip to Main content Skip to Navigation
Journal articles

First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients

B. Maucherat 1 A. Leduc-Pennec 2 N. Fleury 3 Ludovic Ferrer 4, 5 E. Bourbouloux 6 H. Simon 7 M. Le Thiec 1 D. Rusu 1 V. Fleury 1 M. Colombie 1 A. Morel 1 Françoise Kraeber-Bodéré 4, 1 Loïc Campion 8, 9 Caroline Rousseau 4, 1
1 Service de médecine nucléaire [Saint-Herblain]
2 Service de médecine nucléaire [Brest]
3 Délégation à la recherche clinique [CHU Nantes]
4 CRCINA - Département NOHMAD - Equipe 13 - Oncologie nucléaire
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
5 Département de Physique [Saint Herblain]
6 Département d'Oncologie [Saint Herblain]
7 Département de Radio-Oncologie [CHRU Brest]
8 CRCINA - Département NOHMAD - Equipe 11 - Integrative oncogenomics of multiple myeloma pathogenesis and progression
CRCINA - Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers
9 Unité de Biométrie [ICO, Saint Herblain]
Abstract : Aim/Introduction: About 70% of primitive breast cancers had positive estrogen receptors (ER) and may benefit from hormonotherapy. However, ER expression in breast cancer metastases is heterogeneous and about 15% of metastases lost this expression over time. Biopsies were not possible systematically. 16α-18Fluoro-17β-Oestradiol (18FES) is a radiopharmaceutical which predict the response to the first line hormonotherapy. The aim of this prospective study (NCT03442504) was to determine the predictive value of PET at the patient level, before a second line hormonotherapy (2nd- HT) on the FDG response obtained at 6 weeks of treatment. Materials and Methods: We prospectively included 12 ER+ metastatic breast cancer patients, HER2 negative, in progression despite first line hormonotherapy. For the complete study, 60 patients will be included. Due to 2nd-HT proposed by oncologist, we performed 18FES PET-CT (18FES-BL) and 18FDG PET-CT (18FDG-BL) at baseline in the month before the new treatment introduction. Follow-up with 18FDG PET-CT and CT
Complete list of metadatas
https://www.hal.inserm.fr/inserm-02337440
Contributor : Elizabeth Bernardo <>
Submitted on : Tuesday, October 29, 2019 - 2:28:28 PM
Last modification on : Tuesday, November 5, 2019 - 1:32:49 AM
Document(s) archivé(s) le : Thursday, January 30, 2020 - 8:07:26 PM

File

Vignette du document
OP-284 EANM2019.pdf
Files produced by the author(s)

Identifiers

  • HAL Id : inserm-02337440, version 1

Collections

CNRS | CRCINA | UNIV-NANTES | UNIV-ANGERS

Citation

B. Maucherat, A. Leduc-Pennec, N. Fleury, Ludovic Ferrer, E. Bourbouloux, et al.. First results of molecular imaging (FDG and FES) in prospective study for selecting second line hormonotherapy in estrogen receptors positive metastatic breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, Springer Verlag (Germany), 2019, 46 (1), pp.S117. ⟨inserm-02337440⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

33

Files downloads

17

Contact

Informations

CCSD